id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-035210-s9t76pcz	Kaye, Avi Gurion	The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review	2020-11-02		.txt	text/plain	4891	271	44	However, results from this systematic analysis of published research provide positive evidence for the potential efficacy of TCZ to treat severe COVID-19, validating the ethical basis and merit of ongoing randomized controlled clinical trials. After early evidence and recommendations against the use of corticosteroids to treat severe COVID-19 (Russell, Millar & Baillie, 2020; Alhazzani et al., 2020) , a large randomized evaluation of dexamethasone found that the drug significantly reduced 28-day mortality in patients included in the study (rate ratio 0.83; 95% CI [0.74-0.92]; p < 0.001). For the initial screening, the primary search terms were "COVID-19" or "SARS-CoV-2" and "tocilizumab." Papers with primary data for a case-control study comparing mortality rate from severe COVID-19 between TCZ and standard of care (SOC) were included for data synthesis. A systematic review of the clinical data of IL-6 inhibitor tocilizumab (TCZ) for severe COVID-19 points towards efficacy in reducing mortality from the disease.	./cache/cord-035210-s9t76pcz.txt	./txt/cord-035210-s9t76pcz.txt